These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34544107)

  • 1. In brief: Dapagliflozin (Farxiga) for chronic kidney disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):115. PubMed ID: 34544107
    [No Abstract]   [Full Text] [Related]  

  • 2. Dapagliflozin (Farxiga) - a new indication for heart failure.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
    [No Abstract]   [Full Text] [Related]  

  • 3. Empagliflozin (Jardiance) for heart failure.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 5. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
    Maranghi M; Carnovale A; Durante C; Tarquini G; Tiseo G; Filetti S
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):125-37. PubMed ID: 25418019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitors in people with and without T2DM.
    Khunti K
    Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
    [No Abstract]   [Full Text] [Related]  

  • 10. Slowing Progression in CKD: DAPA CKD and Beyond.
    Larmour K; Levin A
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
    [No Abstract]   [Full Text] [Related]  

  • 11. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
    Fioretto P; Stefansson BV; Johnsson E; Cain VA; Sjöström CD
    Diabetologia; 2016 Sep; 59(9):2036-9. PubMed ID: 27306615
    [No Abstract]   [Full Text] [Related]  

  • 13. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
    Kosiborod M; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Javaheri A; Ambery P; Gasparyan SB; Buenconsejo J; Sjöström CD; Langkilde AM; Oscarsson J; Esterline R
    Diabetes Obes Metab; 2021 Apr; 23(4):886-896. PubMed ID: 33319454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
    Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
    Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin: a review of its use in patients with type 2 diabetes.
    Plosker GL
    Drugs; 2014 Dec; 74(18):2191-209. PubMed ID: 25389049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
    Pecoits-Filho R; Perkovic V
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.